MAXONA Pharmaceuticals today announced the preliminary results of the Phase 1 clinical program for MAX-001, which is in development as a New Molecular Entity (NME), non-opioid, non-NSAID oral therapy ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Only around one in 10 common non-surgical and non-invasive treatments for lower back pain are effective, suggests a pooled ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in patients with ...

But a new study has found that only one in 10 treatments for lower back pain are effective, with those that improve symptoms ...

A 60-patient, randomized, double-blind, placebo-controlled phase I clinical study of VAS101 (topical curcumin gel) in osteoarthritis (OA) is underway. The study is being conducted at Clinical Research ...

“The register, developed by Kiwi brand Toniq Limited, is the first of its kind to be approved in New Zealand for pharmacies, ...

WFISD police say the student claimed, “I knocked him out” as he was being escorted from the altercation by administrators.

Parents who have experienced the devastating loss of a child to fentanyl know all too well how critical it is to educate children on the dangers of drugs, especially when it comes to social media.

BOSTON – The high-profile Karen Read murder trial that got underway on April 16 at Norfolk Superior Court in Dedham, Massachusetts ended months later in a mistrial due to a hung jury.

The Week is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.

"No litigant should come to the courtroom knowing they lost their case already before they've filed a brief, their lawyers have argued, before anybody's examined the law.” ...